Bruker Corporation stands as a prominent global developer, manufacturer, and distributor of cutting-edge scientific instruments, alongside comprehensive analytical and diagnostic solutions. Its operations are structured across three distinct segments: Bruker Scientific Instruments (BSI) Life Science, BSI NANO, and Bruker Energy & Supercon Technologies. The company's extensive portfolio for life sciences encompasses a variety of advanced tools, including single and multi-modality systems, sophisticated mass spectrometry platforms, and critical diagnostic solutions. These diagnostics feature the acclaimed MALDI Biotyper for swift pathogen identification, various molecular diagnostic kits (such as genotype and fluorotype offerings), DNA test strips, and fluorescence-based polymerase chain reaction (PCR) technology, notably including SARS-CoV-2 testing solutions for COVID-19 diagnosis and Fluorotyper-SARS-CoV-2 plus kits. Beyond life science, Bruker delivers a wide array of specialized instruments for research, analysis, and process control. This includes portable analytical and bioanalytical detection systems, a full range of X-ray instruments (from analytical tools for electron microscopes to handheld, portable, and mobile X-ray fluorescence spectrometry devices), and sophisticated atomic force microscopy (AFM) instrumentation for non-contact nanometer resolution topography. Furthermore, it supplies automated X-ray metrology, automated AFM defect-detection, and equipment for photomask repair and cleaning. The company also excels in advanced optical fluorescence microscopy and provides critical products and services supporting multi-omics research for drug and biomarker discovery. Within its energy sector, Bruker is a key provider of superconducting materials, particularly metallic low-temperature superconductors, and develops complex tools and devices utilizing these materials, alongside other high-technology tools like synchrotron and beamline instrumentation. Reflecting its commitment to innovation, Bruker Corporation collaborates with Newomics Inc. on an LC-MS platform specifically tailored for drug discovery applications. Established in 1991, the corporation maintains its headquarters in Billerica, Massachusetts.
CEO: Frank H. Laukien. Company website
Bruker Corporation (BRKR) trades at $61.39, down 2.63% on the day, as of Sep 20, 2026 15:01 UTC.
Bruker Corporation has a market capitalisation of $9.35B, calculated from the live BRKR share price and shares outstanding.
BRKR has no meaningful price-to-earnings ratio: Bruker Corporation lost $0.70 per share over the last twelve months, and a P/E is only defined on positive earnings.
Bruker Corporation generated revenue of $3.50B over the trailing twelve months, which puts the stock at 2.67 times sales.
Yes. Bruker Corporation pays a dividend yielding 0.41% on the current share price.
BRKR has traded between $30.09 and $65.30 over the past 52 weeks, and the last price is 6.0% below that high.
No. Bruker Corporation is loss-making, with a net margin of -2.03% over the trailing twelve months.
Wall Street analysts rate BRKR Buy, with an average price target of $59.50, 3.1% below the current price.
Bruker Corporation is classified under the Healthcare sector and the Medical - Devices industry, and is domiciled in US.
Frank H. Laukien is the chief executive of Bruker Corporation, which employs 11,085 people.
QFI Terminal shows BRKR with live charts, full financials, the options chain with gamma exposure, institutional ownership and analyst ratings on one screen. The free plan has no time limit and asks for no card.
Interactive charts, full financials, options chain, gamma exposure, ownership and analyst ratings, all in one institutional-grade terminal.
Open BRKR in Terminal See plans